Unlearn experts outline current reality of AI-powered digital twins and the steps needed to actualize the technology’s potential in clinical practice
Unlearn®, an artificial intelligence research company today announced its peer-reviewed scientific manuscript, entitled "Increasing Acceptance of AI-Generated Digital Twins Through Clinical Trial Applications," was published in the Clinical and Translational Science (CTS) journal.
The manuscript explores the transformative potential of AI-generated digital twins in clinical trials, providing a pathway to increased trust and broader adoption within the medical field. By implementing these solutions in the highly regulated environment of clinical research, the paper illustrates how digital twins can transition from infrequent research applications to becoming a cornerstone of personalized medicine.
“Pharmaceutical companies often hesitate to adopt AI because of perceived risks. But we’re proving how digital twins of patients can overcome these concerns by providing clear, reliable benefits,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “We’re shifting the narrative from skepticism to enthusiasm because the future of more patient-centric medicine depends on it.”
The paper details current applications of digital twins, such as improving the efficiency of clinical trials by optimizing trial design, planning, execution, and analysis. For example, Unlearn’s digital twins of patients forecast individual’s clinical outcomes under the control or standard of care—enabling highly powered trials that maintain sample size or trials with smaller control groups.
The paper also addresses the limitations and challenges of adopting digital twin technology in healthcare, emphasizing the importance of rigorous validation and regulatory compliance. The authors argue that as the technology gains regulatory acceptance, it will pave the way for broader application in clinical practice, ultimately leading to improved patient outcomes and more personalized medicine.
To learn more about Unlearn’s digital twins and see how they optimize clinical trials, visit Unlearn’s TrialPioneer at portal.unlearn.ai/trialpioneer.
About Unlearn
Unlearn is a pioneering artificial intelligence research company that is revolutionizing clinical research with computational models of patients called digital twins. Digital twins provide forecasts of an individual’s health outcomes. They are used in Unlearn’s Platform to help pharmaceutical and biotech companies optimize clinical development and quickly and confidently produce trustworthy outcomes. For more information, please visit www.unlearn.ai or follow @UnlearnAI on Twitter/X and @unlearn-ai on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723818524/en/
Contacts
Alyssa Horowitz
unlearn@pancomm.com
